(2S)-2,6-diamino-N,N-dimethylhexanamide | 143983-51-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2,6-diamino-N,N-dimethylhexanamide
• CAS: 143983-51-1
• 化学式: C₈H₁₉N₃O
• 分子量: 173.258
• InChiKey: VRKYOVZDXJOPDD-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-2,6-diamino-N,N-dimethylhexanamide 以 甲醇 为溶剂， 反应 144.0h， 生成
  参考文献：
  名称：

  1 H NMR方法，用于确定1,2,3-prim，sec，sec-triols的绝对构型。

  摘要：

  可以通过比较tris-（R）-和tris-（S）-MPA酯衍生物的1H NMR光谱来确定1,2,3-prim，sec，sec-三醇的绝对构型。用24个已知绝对配置的三醇和一个使用两个参数Deltadelta（RS）（H3）的协议以及Deltadelta RS（H2）和Deltadelta RS（H3）之间的差=绝对值（Delta（Deltadelta RS ））-介绍了其在确定其他三醇的绝对构型中的应用。

  DOI：

  10.1021/ol0616135
• 作为产物：
  描述：

  N-alpha-Cbz-L-赖氨酸 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-2,6-diamino-N,N-dimethylhexanamide
  参考文献：
  名称：

  Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains

  摘要：

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00533-x

文献信息

• [EN] CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY<br/>[FR] AGONISTES CNP À LIBÉRATION CONTRÔLÉE PRÉSENTANT UNE MEILLEURE STABILITÉ À NEP
  申请人：ASCENDIS PHARMA GROWTH DISORDERS AS

  公开号：WO2017118700A1

  公开（公告）日：2017-07-13

  The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

  本发明涉及具有至少5倍长的降解半衰期的控制释放的CNP激动剂，在体外NEP降解测定中比相应释放的CNP激动剂，以及包含所述控制释放的CNP激动剂的药物组合物，它们的用途和治疗方法。
• Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use
  申请人：Bajjalieh William

  公开号：US20100087440A1

  公开（公告）日：2010-04-08

  The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

  本发明涉及磷脂酰肌醇3-激酶（PI3K）的小分子抑制剂，该酶与多种恶性肿瘤相关，如卵巢癌、宫颈癌、乳腺癌、结肠癌、直肠癌和胶质母细胞瘤等。因此，本发明的化合物可用于治疗、预防和/或抑制这些疾病。
• Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use
  申请人：Bajjalieh William

  公开号：US20110207712A1

  公开（公告）日：2011-08-25

  The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

  本发明涉及磷脂酰肌醇3-激酶（PI3K）的小分子抑制剂，PI3K与多种恶性肿瘤相关，如卵巢癌、宫颈癌、乳腺癌、结肠癌、直肠癌和胶质母细胞瘤等。因此，本发明化合物可用于治疗、预防和/或抑制这些疾病。
• N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Exelixis, Inc.

  公开号：EP1931645A2

  公开（公告）日：2008-06-18
• COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER
  申请人：Exelixis, Inc.

  公开号：EP2139483A2

  公开（公告）日：2010-01-06